Przebieg i wyniki leczenia chorych na rozlanego chloniaka (DLBCL) żolądka
Author(s): ElÅ¼bieta StarosÅ?awska, Aneta DobrzyÅ?ska-Rutkowska, Anna Twardosz, Maria Luiza Kusz, Iwona Hus, Maria Mazurkiewicz
It is still under discussion what is the optimal treatment of primary gastric diffuse large Bcell lymphoma (PG-DLBCL). Currently, an antracyclins-based chemotherapy combined with rituximab is thought to facilitate complete remission without the need for a surgical intervention. The course and results of the treatment of patients suffering from primary gastric diffuse large B-cell lymphoma in the Centre of Oncology of Lubelska Land in the period 2003-2010 have been presented. 7 patients were enrolled in the study, with four of them subject to initial surgical treatment and six – to immunochemotherapy under the R-CHOP-21 regime. Only one subject included in the study underwent CHOP chemotherapy. In all patients complete remission (CR) was achieved and sustained from 79 to 3 months.
Share this article
Submitted PhD thesis in Biotechnology at GITAM University, Vizag.
The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
Saudi Arabia Critical Care/TPN
Clinical Pharmacist Ministry of Health,
Riyadh, Saudi Arabia.
Department of Radiation Oncology
Asahi University Hospital
Gifu city, Gifu, Japan
Maher Abdel Fattah Al-Shayeb
Department of Surgical Sciences, Ajman University, UAE
Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)
Citations : 61
- Euro Pub
- Google Scholar
- Medical Project Poland
- Cancer Index
- Gdansk University of Technology, Ministry Points 20